Semaglutide vs Tirzepatide: How They Compare

Two approved medications, not research compounds

Semaglutide and tirzepatide are both FDA approved prescription medications. Neither is a research chemical, and neither is sold that way. Semaglutide is approved as Ozempic for type 2 diabetes and as Wegovy for chronic weight management. Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Both require a prescription, a diagnosis that fits the labeled use, and ongoing medical supervision.

This article compares the two drugs through the clinical trials that supported their approval. It does not offer dosing guidance or suggest either drug is appropriate for a given person. That decision belongs to a licensed prescriber who knows a patient's full medical history.

How each drug works in the body

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1, short for glucagon like peptide 1, is a hormone your gut releases after you eat. It slows how fast the stomach empties, tells the brain you are full, and helps the pancreas release insulin when blood sugar rises. Semaglutide mimics this hormone and activates the same receptors, which is why it lowers blood sugar in diabetes and reduces appetite in weight trials.

Tirzepatide goes a step further. It is a dual GIP and GLP-1 receptor agonist, meaning it activates both the GLP-1 receptor described above and the receptor for a second gut hormone, GIP (glucose dependent insulinotropic polypeptide). GIP is released alongside GLP-1 after meals and has its own effects on insulin release and fat tissue. Researchers believe combining both signals produces a stronger effect on appetite and blood sugar than activating GLP-1 receptors alone, which is one proposed explanation for the trial differences described below. Both drugs are given as a subcutaneous injection roughly once a week, using a prefilled pen device, and both are intended for long term use alongside diet and activity changes, not as a short course.

From diabetes drug to weight management approval

Both compounds followed a similar regulatory path. Semaglutide reached the market first as Ozempic, approved for type 2 diabetes, before its higher dose weight management form, Wegovy, won its own approval in June 2021. Tirzepatide followed the same order: it launched as Mounjaro for type 2 diabetes, and the FDA approved the weight management version, Zepbound, in November 2023. In both cases, the weight management approval rested on a dedicated obesity trial program in people without diabetes, run separately from the diabetes program, which is why the STEP and SURMOUNT trials described below enrolled participants who did not have diabetes.

What the major weight trials found

STEP 1: semaglutide in adults with obesity

The STEP 1 trial, led by Wilding and colleagues and published in the New England Journal of Medicine in 2021, enrolled over 1,900 adults with obesity or overweight who did not have diabetes. Participants received once weekly semaglutide 2.4 milligrams or placebo for 68 weeks, alongside diet and activity counseling for both groups. The semaglutide group lost an average of about 15 percent of body weight, compared with roughly 2.4 percent in the placebo group. Most people in the semaglutide group lost at least 5 percent of their starting weight.

SURMOUNT 1: tirzepatide in adults with obesity

The SURMOUNT 1 trial, led by Jastreboff and colleagues and published in NEJM in 2022, tested tirzepatide at 5, 10, and 15 milligram doses against placebo in over 2,500 adults with obesity or overweight, again without diabetes, over 72 weeks. Average weight loss ranged from about 16 percent at the lowest dose to about 22.5 percent at the highest dose, with the placebo group losing roughly 3 percent. Around nine out of ten participants on tirzepatide lost some weight during the trial.

Trial populations, durations, and doses differ enough that these two studies cannot be compared directly as a head to head result. For that, researchers ran a separate trial.

The head to head trial: SURPASS 2

The SURPASS 2 trial, led by Frias and colleagues and published in NEJM in 2021, is the closest available head to head comparison. It enrolled 1,879 adults with type 2 diabetes and randomly assigned them to weekly tirzepatide at 5, 10, or 15 milligrams, or weekly semaglutide at 1 milligram, over 40 weeks. All three tirzepatide doses were not inferior to semaglutide for lowering blood sugar, and each was statistically superior on that measure. Tirzepatide groups also lost more body weight on average than the semaglutide group. This was a diabetes trial, and semaglutide was tested at its diabetes dose rather than its higher weight management dose, which matters when reading the result.

A cardiovascular finding worth noting

Weight loss trials mainly track the scale, but semaglutide also has data on heart outcomes. The SELECT trial, led by Lincoff and colleagues and published in NEJM in 2023, followed over 17,000 adults with existing cardiovascular disease and overweight or obesity, without diabetes, for a median of about three years. Participants taking semaglutide had fewer cardiovascular deaths, heart attacks, and strokes than those on placebo, a roughly 20 percent relative reduction in that combined outcome. A comparable large scale cardiovascular outcomes trial for tirzepatide in a similar population had not been published as of this writing, so this specific finding cannot yet be compared directly between the two drugs.

Side effects and safety considerations

Both drugs share a similar side effect pattern because both slow digestion. Nausea, vomiting, diarrhea, and constipation are the most common complaints, and they tend to be worst while the dose is being raised. Prescribers typically start at a low dose and increase it gradually on a titration schedule to reduce these effects, rather than starting at the target dose.

Both drug labels carry a warning about gallbladder related problems, including gallstones, since rapid weight loss itself raises that risk. Both also carry a boxed warning about thyroid C cell tumors, based on findings in rodent studies; it is not confirmed in humans, and people with a personal or family history of certain thyroid cancers are advised against these drugs. Other labeled concerns for both drugs include the possibility of acute pancreatitis, changes in kidney function linked to dehydration from vomiting or diarrhea, injection site reactions, and a risk of low blood sugar when either drug is combined with insulin or certain diabetes medications. Neither drug is sold or intended for use without a prescription and clinical monitoring, and both labels advise caution about interactions with other medications that also slow digestion.

What ongoing use of either drug involves

Neither drug is a short course. Both trial programs ran well over a year, and both drugs are prescribed for long term, continuous use alongside diet and activity changes, since weight tends to return once the medication stops, a pattern both trial programs also documented in their withdrawal and extension data. Starting either drug typically means a baseline visit to review medical history and lab work, a gradual dose increase over weeks to months to reduce nausea, and follow up visits to check weight, blood sugar where relevant, and side effects. Pharmacies dispense both as prefilled injection pens with printed dosing instructions from the prescriber, not as a compound the patient measures or mixes at home. None of this article substitutes for that process, and none of it should be read as a suggestion to source either drug outside a licensed prescription.

Choosing between them is a medical decision

Trial averages describe groups, not individuals. A person's response to either drug depends on their starting weight, other health conditions, other medications, cost and insurance coverage, and how well they tolerate the gastrointestinal side effects during titration. Some people do better on one drug than the other for reasons trials cannot fully predict. Trial populations also skew toward people willing and able to complete a year or more of study visits, which is not identical to the general population seeking either drug.

Cost and coverage often decide the question before biology does. List prices for both drugs run over a thousand dollars a month in the United States, and insurance coverage for the weight management indications varies widely by plan, employer, and state. A prescriber weighing semaglutide against tirzepatide for a given patient is balancing trial results, other health conditions, drug interactions, and practical access, not picking a winner from a leaderboard. This is why the choice sits with a licensed prescriber, not with trial statistics alone.

If you want to learn more about how GLP-1 and related metabolic peptides are researched and referenced, LifeConverted keeps a browsable browsable peptide reference library covering the compounds discussed across this site.

Common questions

Is semaglutide or tirzepatide more effective for weight loss? In head to head diabetes trials, tirzepatide produced larger average reductions in body weight and blood sugar than semaglutide. Individual results vary, and a prescriber weighs many factors beyond trial averages before recommending either drug.

Can I buy semaglutide or tirzepatide as a research peptide? No. Both are approved prescription drugs sold under brand names through licensed pharmacies with a valid prescription. They are not research chemicals, and products sold outside that system are not verified or regulated.

What are the main side effects of semaglutide and tirzepatide? Both drug classes commonly cause nausea, vomiting, diarrhea, and constipation, especially while the dose is being raised. Both carry labeled warnings about gallbladder problems and a theoretical thyroid C cell tumor risk seen in animal studies.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.